Abstract: The disclosure relates to methods for coloring keratinous substrates using solubilized vat dyes, as well as compositions and kits suitable for carrying out the methods. The disclosure also relates to novel solubilized vat dyes.

Abstract: A cosmetic composition including: (A) a silicone film-forming agent, and (B) an organopolysiloxane having a polyalkylene oxide moiety and a cationic group other than the component (A), wherein the content of water is 50% by mass or less. The cosmetic composition is a hair cosmetic composition or a hair dye composition.

Abstract: Described herein are aerosol compositions useful for deodorant and/or antiperspirant applications. Such compositions are substantially free of cyclomethicone. Also described are methods of making and using the same.

Abstract: The use of peptide compounds to reduce the production of skin sebum and a composition comprising peptide compounds and their use for cosmetic treatments or skin diseases and disorders, such as acne vulgaris, in the fields of chemistry, pharmacy, and cosmetology.

Abstract: A method of dechlorinating skin, especially dechlorinating skin, hair and/or nails of humans including contacting said skin, hair and/or nails with an aqueous composition for sufficient time to reduce halogen effects on the skin, hair and/or nails. The aqueous composition comprising water and an oil-soluble bis-ascorbate in a weight ratio of about 0.1 to 25% by weight of the total aqueous composition, a surfactant, and a buffering agent maintaining pH of the aqueous composition in anaerobic conditions at between 7.8 and 8.3 at room temperature for at least 10 days. Optionally there is 0.05% to 30% by weight of suspended carbon particles.

Abstract: Disclosed herein are skin care compositions, comprising vitamin E (e.g., alpha-tocopherol), a thiourea derivative of histidine (e.g., ergothioneine), a vitamin B3 compound (e.g., niacinamide) and/or a pyrrolidone carboxylic acid and/or a salt thereof (e.g., sodium PCA) as well as to methods of using these compositions.

Abstract: Disclosed herein are skin care compositions, comprising vitamin E (e.g., alpha-tocopherol), a thiourea derivative of histidine (e.g., ergothioneine), a vitamin B3 compound (e.g., niacinamide) and/or a pyrrolidone carboxylic acid and/or a salt thereof (e.g., sodium PCA) as well as to methods of using these compositions.

Abstract: A shaving aid composition includes a water-soluble polymer, such as polyethylene oxide, and a cellulosic cationic polymer, such as a polyquaternium. The shaving aid composition may be substantially anhydrous and solid. A wet shave implement may include the shaving aid composition. For example, the shaving aid composition may be in a shaving aid strip, a lubrication box, or any combination thereof. A method to make a shaving aid may include selecting the water-soluble polymer, selecting the cationic polymer, and combining the water-soluble polymer and the cationic polymer to form the shaving aid composition. A method to use the shaving aid composition may include contacting the shaving aid composition with a solvent to activate the water-soluble polymer and to deposit at least the cellulosic cationic polymer on hair and/or skin from the wet shave implement during a shave.

Abstract: Composite particles that are biodegradable and easy to handle while maintaining the characteristics of cellulose nanofibers, a method of producing composite particles, a dry powder containing the composite particles, and a skin application composition and a method of producing the skin application composition. A composite particle contains at least one type of particle and fine cellulose with which at least part of a surface of the particle is coated, wherein the particle and the fine cellulose are inseparable.

Abstract: Biocompatible UV-absorbing nanoparticles or microparticles that can be embedded in the skin using techniques such as those used to create a tattoo with tattoo ink. The “tattoo” using the biocompatible UV-absorbing nanoparticles or microparticles provides skin protection against sunburn, photoaging, and skin cancers in a permanent or semi-permanent way, but remain clear in the visible light spectrum, or matched closely to the user's specific skin tone. These particles can be solid uniform UV-absorbers, microencapsulated UV-absorbers, or UV-absorbing material embedded in or coated on solid materials. Long-term sun protection from an invisible (does not change the color of the skin) material, embedded in the skin (dermis layer).

Abstract: The present disclosure relates to air texture altering systems and methods that, among other things, loosen the curl pattern of the hair without straightening the hair using oils, other natural ingredients, and low concentrations of sodium hydroxide, in a manner that reduces the use of harsh and/or synthetic chemicals.

Abstract: A composition consisting of a polar phase and a non-polar phase, wherein the polar phase contains at least 40% by weight of glycerol and at least 20% by weight of water, based on the total weight of the polar phase, the composition contains from 0.5 g to 4 g of lecithin per 100 g of composition, and the non-polar phase contains at least one extract selected from an extract of mint (Mentha arvensis or Mentha x piperita), an extract of clove tree (Syzygium aromaticum), an extract of ginger (Zingiber officinale) and an extract of thyme (Thymus vulgaris).

Abstract: The group of inventions relates to healthcare, concerns dentistry. The group of inventions includes a composition for the treatment and/or prevention of the oral diseases comprising an effective amount of aqueous and lipophilic extracts of aspen bark and at least one or more auxiliary compounds for the treatment and/or prevention, also includes a method of treatment and the use of a composition for the manufacture of a product for the treatment and/or prevention of the oral diseases. The group of inventions is characterized by high efficiency in the treatment and/or prevention of various the oral diseases, provides high-quality hygienic cleaning of the surface of the teeth and oral cavity. The use of a group of inventions makes it possible to reduce the likelihood of the occurrence and/or elimination of inflammation, as well as ulcers and erosions of the oral cavity in situations that contribute to their formation.

Abstract: Embodiments disclosed herein include nasal formulations and methods of use. In some embodiments, nasal formulations disclosed herein can include at least one agent comprising latanoprost, or pharmaceutically acceptable salt thereof; at least one adherence agent for prolonging nasal mucosal interaction of the formulation; and optionally, at least one pharmaceutically acceptable carrier or diluent. In some embodiments, methods include, but are not limited to, methods of increasing cerebrospinal fluid (CSF) outflow and reducing intracranial pressure (ICP) in subjects in need thereof.

Abstract: An oil-in-water emulsion for intravitreal administration, especially injection, including an active ingredient, an oil, a mixture of two non-ionic surfactants and water, the emulsion having a droplet size ranging from about 100 to about 200 nm. The emulsion avoids troubles of vision after administration into the vitreous body. The emulsion provides good therapeutic activity of the active ingredient for treating eye diseases or conditions, such as an eye disease or condition of the posterior segment of the eye.

Abstract: This disclosure is directed to ophthalmic suspensions for dry eye and other ocular indications that provide long-lasting on eye benefits. The disclosure provides methods of increasing lipid layer thickness and methods of lubricating an eye. The disclosure also provides methods of maintaining integrity of an eye's tear film layers which increases the eye's lipid layer thickness and methods of recreating or building one or more layers of an eye's tear film.

Abstract: A solid oral pharmaceutical composition for delivery of a pharmaceutically acceptable active ingredient to an animal where the composition comprises an isoxazoline compound, a solvent and an excipient, a process for the manufacture of such solid oral pharmaceutical composition and a method of controlling a parasite infection administering such solid oral pharmaceutical composition.

Abstract: A soft, chewable and orally dissolvable and/or disintegrable product includes a biopolymer-sugar based matrix and botanical powder dispersed throughout the biopolymer-sugar based matrix. The biopolymer-sugar based matrix includes at least one biopolymer, at least one sugar and optional additives. Soft, chewable and orally dissolvable and/or disintegrable product can also include flavor beads.

Abstract: The present invention relates to novel pharmaceutical combinations and compositions comprising sucralfate and magnesium alginate, a process for their preparation and the use of said compositions in therapy, in particular for the treatment and/or prevention of disorders of the upper gastro-intestinal tract.

Abstract: The present disclosure relates to novel topical formulations containing a tofacitinib and or a fingolimod that are useful for treating dermatological conditions, such as atopic dermatitis, psoriasis, vitiligo and eczema.

Abstract: The present invention relates to a drug delivery system at least comprising a drug encapsulated in a polymeric nano vesicle (polymersome), wherein the drug component is an anthracycline derivative according to the formula I wherein R1 is selected from the group consisting of H, F, —OMe or —OEt; R2 is selected from the group consisting of H, —OMe, methyl or ethyl; R3 is selected from the group consisting of H, methyl or ethyl, and R4 is H or a protecting group; the polymersome is formed by polymers comprising PEG, PEA, PCL, PTMC or PTMB building blocks or combinations thereof, wherein the polymersome polymers are, at least in part, functionalized by chemically attaching via a linker group L a targeting moiety, wherein the targeting moiety is selected from the group consisting of antibodies, peptides, aptamers or mixtures thereof.

Abstract: Disclosed is a pharmaceutical nanoparticle containing a core and a shell coating the core. The core contains (3-{4-[2-({4-[3-(3-cyclohexylamino-propylamino)-propyl]-oxazol-2-ylmethyl}-amino)-6-methyl-pyrimidin-4-ylamino]-piperidin-1-yl}-3-oxo-propylamino)-acetic acid or a salt thereof, 1,2-dioleoyl-sn-glycero-3-phosphate, and an anionic polymer. The shell contains a lipid. Also disclosed is a method for preparing such as pharmaceutical nanoparticle. Further provided are a liposome containing a lipid bilayer enclosing an aqueous core and its preparation method.

Abstract: Disclosed are a sustained-release pharmaceutical formulation of a fused tricyclic ?-amino acid derivative and a preparation method therefor. The fused tricyclic ?-amino acid derivative is a compound represented by formula (I) or a stereoisomer, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or a eutectic crystal thereof.

Abstract: The present invention relates to a coated tablet composition comprising ibrutinib and one or more pharmaceutically acceptable excipients, characterized in that: ?Ibmtinib is form C, having characteristic peaks in the X-ray powder diffraction pattern at the following 2 theta (±0.2) angles: 6.9°, 18.2°, 19.2°, 19.6° and 23.0°, measured using a Cu K? radiation; and ?The coating is free of plasticizer. The invention further relates to the use of said composition as a medicament, particularly in the treatment of chronic lymphocytic leukaemia (CLL), mantle cell lymphoma (MCL), Waldenström's macroglobulinaemia (WM) and chronic graft-versus-host disease (cGVHD).

Abstract: Disclosed is a process for non-stop production of encapsulated probiotics, in which an alginate hydrogel is spontaneously formed through a simple process of culturing probiotics in a medium containing an alginate, a salt that forms a hydrogel by binding to alginic acid, preferably an insoluble carbonate, and optionally an encapsulation enhancer, and probiotics are encapsulated by the alginate hydrogel, thereby not only greatly improving the probiotic encapsulation process but also remarkably improving the freeze-drying viability, heat tolerance, shelf stability, and in-vivo stability (acid resistance and bile resistance) of probiotics.

Abstract: Described herein are an aspirin or active aspirin derivative and a COX-2 inhibitor, at least one of which has an enteric or partial enteric coating, administered in combination yet delivered sequentially, for the treatment and prophylactic treatment of diseases, symptoms and conditions. In some embodiments, the COX-2 inhibitor has the enteric coating; however, the aspirin or active aspirin derivative may additionally or alternately have the enteric coating. In all embodiments, the drug having the enteric coating or enteric formulation is targeted for absorption in the small intestine or colon, or both the small intestine and the colon.

Abstract: Provided herein are lipid formulations of reduced size, comprising a lipid and a capsid free, non-viral vector (e.g., ceDNA), and methods of producing said lipid formulations. Lipid particles (e.g., lipid nanoparticles) of the disclosure include a lipid formulation that can be used to deliver a capsid-free, non-viral DNA vector to a target site of interest (e.g., cell, tissue, organ, and the like).

Abstract: Ionizable phospholipids and compositions and methods relating thereof are provided herein. In some aspects, the ionizable phospholipids provided herein may be formulated in compositions which contain a nucleic acid and one or more helper excipients. In some aspects, these compositions may also be used to treat diseases or disorders with a therapeutic nucleic acid.

Abstract: Ionizable cationic lipids, methods for synthesizing them, as well as intermediates useful in synthesis of these lipids and methods of synthesizing the intermediates are disclosed. The ionizable cationic lipids are useful as a component of lipid nanoparticles (LNP), which in turn can be used for the delivery of nucleic acids into cells in vivo or ex vivo. LNP compositions are also disclosed, including LNP comprising a functionalized lipid to enable conjugation of a binding moiety, and targeted LNP (tLNP), that is a LNP in which a binding moiety has been conjugated to the functionalized lipid and can serve as a targeting moiety to direct the tLNP to a desired tissue or cell type.

Abstract: Provided herein is a biodegradable polymeric nanoparticle formed of hybrid block copolymers comprising a di-block copolymer methoxy-poly(ethylene glycol)-poly(lactic acid) (m-PEG-PLA) and/or a penta-block copolymer poly(lactic acid)-poly(ethylene glycol)-poly(propylene glycol)-poly(ethylene glycol)-poly(lactic acid) (PLA-PEG-PPG-PEG-PLA). Also provided herein are methods of preparing biodegradable polymeric nanoparticles.

Abstract: A magnetoelectric nanocomposite (MEN) is described. The MEN are used as a colorectal cancer treatment. The MEN includes a shell having at least one ferroelectric compound and a rare earth (R) metal doped spinel ferrite nanoparticle (SFNP) core, of a formula of CoxMn1-xR2-yFeyOz wherein x= 0.1-0.9, y = 1.90-1.99, and z = 3-5; and R is at least one rare earth metal selected from the group consisting of cerium (Ce), europium (Eu), gadolinium (Gd), terbium (Tb) and thulium (Tm). A method of making MENs is also provided.

Abstract: A fiber may comprise an electrospun polymer and a pharmaceutical. The pharmaceutical may be dispersed within the electrospun polymer, and may have the form of a crystal, an oil, or a combination thereof. A method of making an electrospun fiber may comprise configuring a receiving surface to receive a polymer fiber, applying a charge to one or more of the receiving surface, a polymer injection system, and a polymer solution ejected from the polymer injection system, and depositing a polymer solution ejected from the polymer injection system onto the receiving surface. The polymer solution may comprise a polymer and a pharmaceutical. A method of treating a disorder in a subject may comprise obtaining such a fiber having an effective amount of a pharmaceutical, applying the fiber to an oral region of the subject, and allowing the fiber to disintegrate, thereby delivering the effective amount of the pharmaceutical to the subject.

Abstract: Methods are disclosed for the reduction of stress in ruminants in need thereof by administering propanediol mononitrate or chloroform or a composition which includes propanediol mononitrate or chloroform to a ruminant prior to experiencing stress, while experiencing stress and/or after having experienced stress.

Abstract: A method of treating or alleviating symptoms of a disorder or a condition in a subject, including identifying the disorder or the condition of a subject, the disorder or condition identified based on first measures of a bloodstream concentration of a substance or a blood stream count of cellular elements, orally administering to said subject an amount of cannabidiol over a period of time effective treat or alleviate symptoms of said disorder or said condition, altering the bloodstream concentration of said substance or said blood stream count of cellular elements, and assessing efficacy of treating or alleviating symptoms of the disorder or the condition evidenced by comparing second measures of the bloodstream concentration of the substance or the blood stream count of cellular elements after the period time to the first measures of bloodstream concentration of the substance or the blood stream count of cellular elements.

Abstract: The present application relates to an anticoccidial composition comprising a stilbene-based compound, and a use thereof. A composition comprising a compound or a salt thereof, according to one embodiment, has excellent effects of direct killing of protozoa that can induce coccidiosis, inhibiting the cell penetration of the protozoa and/or inhibiting the intracellular proliferation of the protozoa, and preventing, alleviating, and treating in vivo coccidiosis.

Abstract: Disclosed is a composition for anti-aging or skin regeneration comprising Okanin, and use of Okanin or a salt thereof and, more particularly, to a composition for anti-aging or skin regeneration comprising Okanin represented by the following formula (1) or a salt thereof, and use of Okanin or a salt thereof.

Abstract: Compositions comprising select aryl alkanones and the use thereof in the treatment of melanoma and non-melanoma skin cancer.

Abstract: Long term storage stable injectable phytonadione containing liquid pharmaceutical formulations are disclosed. The compositions can include phytonadione or pharmaceutically acceptable salts thereof; an antioxidant; buffer, pH adjusting agent and a pharmaceutically acceptable fluid. The methods of preparing the formulation as well as methods of treatment of phytonadione deficiency diseases using the same are also disclosed.

Abstract: The present invention describes stable topical barrier compositions comprising primary polyamines and uses thereof for protecting the skin from external stressors, for improving skin's moisture and fort stimulating healing of the skin. These compositions may be used in a variety of cosmetic and therapeutic applications including for promoting wound healing, for reducing or preventing the formation of hypertrophic scar tissue, for reducing or preventing skin irritation and inflammation, for increasing skin's moisture and/or for reducing or preventing skin's signs of aging.

Abstract: The present disclosure relates to compositions comprising racemic ketamine, or a pharmaceutically acceptable salt thereof, for use in treating psychiatric disorders such as suicidality, suicidal ideation, major depressive disorder, treatment-resistant depression, and post-traumatic stress disorder.

Abstract: The present invention relates to the preventive and therapeutic uses of acid sphingomyelinase inhibitors (FIASMAs) such as psychotropic medications and non-psychotropic compounds having FIASMA activity, for lowering the risk of death and/or intubation in patient suffering from a viral infection caused by at least one betacoronavirus, in particular by the SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2).

Abstract: The use of a mitoxantrone preparation in the preparation of a drug for diagnosing and treating breast cancer. Provided is the use of mitoxantrone and/or a pharmaceutically acceptable salt thereof in the preparation of a lymphatic tracer in a disease associated with breast resection. No local or systemic toxic and side effects are seen after local injection of the preparation, suggesting that the preparation has good tolerance, effectiveness and safety, which provides a new treatment idea for thoroughly curing breast cancer in a breast cancer patient.

Abstract: The invention also relates to processes for producing abuse deterrent pharmaceutical compositions comprising highly pure amphetamine and amphetamine-class compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds, and to methods of manufacturing, delivering, and using the amphetamine compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds.

Abstract: The disclosure provides for a combination therapy comprising different classes of medications for the treatment of tinnitus and other medical conditions, and methods of treatment thereof.

Abstract: Provided herein are methods of treating cancer, comprising administering AMXT 1501, or a pharmaceutically acceptable salt thereof, orally, and difluoromethylornithine (DFMO), or a pharmaceutically acceptable salt thereof, intravenously to a subject in need thereof.

Abstract: The present disclosure relates to a method for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF 1-PN), by orally administering an effective amount of mirdametinib to the patient, where an amount of mirdametinib is administered on the first day of treatment to provide (i) an AUC0-tau less than 400 ng·h/mL, (ii) a Cmax no more than 40 ng/mL, or (iii) both.

Abstract: The present disclosure relates to a method for treating certain types of tumors or cancers, such as plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), by orally administering an effective amount of mirdametinib to the patient, where an amount of mirdametinib is administered on the first day of treatment to provide (i) an AUC0-tau less than 400 ng h/mL, (ii) a Cmax no more than 40 ng/mL, or (iii) both.

Abstract: The methods include treating atypical teratoid/rhabdoid tumor by administration of HydroxyUreaMethyl Acylfulvene. Some embodiments relate to treatment of atypical teratoid/rhabdoid tumor by administration of HydroxyUreaMethyl Acylfulvene to a population or subject expressing SMARCB1.

Abstract: Provided is a method for treating cancer by administering to a subject in need thereof with a pharmaceutical composition including a benzenesulfonamide derivative and at least one other therapeutic agents in a different classification of anticancer agents.

Abstract: The present disclosure provides peripherally acting cannabidiolic acid (CBDA)-containing compositions and methods of using thereof for treating or enhancing female sexual function. In some embodiments, the compositions are provided in the form of a topical dosage form, which is applied to female genitalia shortly prior to sexual activity.